March 22 (Reuters) - A panel of U.S. Food and Drug
Administration (FDA) advisers on Wednesday voted against the
effectiveness of Biogen Inc's experimental treatment
for an inherited form of amyotrophic lateral sclerosis (ALS).
(Reporting by Bhanvi Satija and Raghav Mahobe in Bengaluru;
Editing by Shounak Dasgupta)